1719 related articles for article (PubMed ID: 31109652)
41. Dupilumab: A review of its use in the treatment of atopic dermatitis.
Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
[TBL] [Abstract][Full Text] [Related]
42. Conjunctivitis in dupilumab clinical trials.
Akinlade B; Guttman-Yassky E; de Bruin-Weller M; Simpson EL; Blauvelt A; Cork MJ; Prens E; Asbell P; Akpek E; Corren J; Bachert C; Hirano I; Weyne J; Korotzer A; Chen Z; Hultsch T; Zhu X; Davis JD; Mannent L; Hamilton JD; Teper A; Staudinger H; Rizova E; Pirozzi G; Graham NMH; Shumel B; Ardeleanu M; Wollenberg A
Br J Dermatol; 2019 Sep; 181(3):459-473. PubMed ID: 30851191
[TBL] [Abstract][Full Text] [Related]
43. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C
Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175
[TBL] [Abstract][Full Text] [Related]
44. No Increased Risk of Overall Infection in Adults with Moderate-to-Severe Atopic Dermatitis Treated for up to 4 Years with Dupilumab.
Blauvelt A; Wollenberg A; Eichenfield LF; Zhang H; Sierka D; Khokhar FA; Vakil J; Shabbir A; Marco AR; Cyr SL
Adv Ther; 2023 Jan; 40(1):367-380. PubMed ID: 36318387
[TBL] [Abstract][Full Text] [Related]
45. Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis-A pooled analysis of trial data.
Paller AS; Beck LA; Blauvelt A; Siegfried EC; Cork MJ; Wollenberg A; Chen Z; Khokhar FA; Vakil J; Zhang A; Bansal A; Cyr SL
Pediatr Dermatol; 2022 Mar; 39(2):187-196. PubMed ID: 35083774
[TBL] [Abstract][Full Text] [Related]
46. IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis.
Paller AS; Tan JKL; Bagel J; Rossi AB; Shumel B; Zhang H; Abramova A
Br J Dermatol; 2022 Mar; 186(3):496-507. PubMed ID: 34726270
[TBL] [Abstract][Full Text] [Related]
47. Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD study.
Merola JF; Chiou AS; During E; Costanzo A; Foley P; Alfalasi A; Gogate S; Pinter A; Dodiuk-Gad R; Simon D; Tauber M; Weller R; Pereyra-Rodriguez JJ; Ardeleanu M; Wu J; Ozturk ZE
Br J Dermatol; 2023 Nov; 189(6):685-694. PubMed ID: 37562034
[TBL] [Abstract][Full Text] [Related]
48. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
Beck LA; Thaçi D; Hamilton JD; Graham NM; Bieber T; Rocklin R; Ming JE; Ren H; Kao R; Simpson E; Ardeleanu M; Weinstein SP; Pirozzi G; Guttman-Yassky E; Suárez-Fariñas M; Hager MD; Stahl N; Yancopoulos GD; Radin AR
N Engl J Med; 2014 Jul; 371(2):130-9. PubMed ID: 25006719
[TBL] [Abstract][Full Text] [Related]
49. Dupilumab treatment induced similar improvements in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis with baseline Eczema Area and Severity Index Score <24 or ≥24.
Offidani A; Stingeni L; Neri I; Cipriani F; Chen Z; Rossi AB; Lu Y; Moretti D
Ital J Dermatol Venerol; 2022 Feb; 157(1):39-46. PubMed ID: 33878856
[TBL] [Abstract][Full Text] [Related]
50. Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial.
Tsianakas A; Luger TA; Radin A
Br J Dermatol; 2018 Feb; 178(2):406-414. PubMed ID: 28845523
[TBL] [Abstract][Full Text] [Related]
51. Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis.
Paller AS; Siegfried EC; Cork MJ; Arkwright PD; Eichenfield LF; Ramien M; Khokhar FA; Chen Z; Zhang A; Cyr SL
Paediatr Drugs; 2024 Mar; 26(2):163-173. PubMed ID: 38267692
[TBL] [Abstract][Full Text] [Related]
52. The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study.
Zhao Y; Wu L; Lu Q; Gao X; Zhu X; Yao X; Li L; Li W; Ding Y; Song Z; Liu L; Dang N; Zhang C; Liu X; Gu J; Wang J; Geng S; Liu Q; Guo Y; Dong L; Su H; Bai L; O'Malley JT; Luo J; Laws E; Mannent L; Ruddy M; Amin N; Bansal A; Ota T; Wang M; Zhang J
Br J Dermatol; 2022 Apr; 186(4):633-641. PubMed ID: 34358343
[TBL] [Abstract][Full Text] [Related]
53. Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis.
Wang FP; Tang XJ; Wei CQ; Xu LR; Mao H; Luo FM
J Dermatol Sci; 2018 May; 90(2):190-198. PubMed ID: 29472119
[TBL] [Abstract][Full Text] [Related]
54. Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials.
Barbarot S; Wollenberg A; Silverberg JI; Deleuran M; Pellacani G; Armario-Hita JC; Chen Z; Shumel B; Eckert L; Gadkari A; Lu Y; Rossi AB
J Dermatolog Treat; 2022 Feb; 33(1):266-277. PubMed ID: 32347763
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Blauvelt A; Teixeira HD; Simpson EL; Costanzo A; De Bruin-Weller M; Barbarot S; Prajapati VH; Lio P; Hu X; Wu T; Liu J; Ladizinski B; Chu AD; Eyerich K
JAMA Dermatol; 2021 Sep; 157(9):1047-1055. PubMed ID: 34347860
[TBL] [Abstract][Full Text] [Related]
56. Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial.
Simpson EL; Silverberg JI; Worm M; Honari G; Masuda K; Syguła E; Schuttelaar MLA; Mortensen E; Laws E; Akinlade B; Patel N; Maloney J; Paleczny H; Delevry D; Xiao J; Dubost-Brama A; Bansal A
J Am Acad Dermatol; 2024 Jun; 90(6):1190-1199. PubMed ID: 38296199
[TBL] [Abstract][Full Text] [Related]
57. Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6-11 Years of Age with Severe Atopic Dermatitis.
Cork MJ; Thaçi D; Eichenfield LF; Arkwright PD; Chen Z; Thomas RB; Kosloski MP; Dubost-Brama A; Prescilla R; Bansal A; Levit NA
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2697-2719. PubMed ID: 37750994
[TBL] [Abstract][Full Text] [Related]
58. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).
Silverberg JI; Gooderham MJ; Paller AS; Deleuran M; Bunick CG; Gold LFS; Hijnen D; Calimlim BM; Lee WJ; Teixeira HD; Hu X; Zhang S; Yang Y; Grada A; Platt AM; Thaçi D
Am J Clin Dermatol; 2024 May; 25(3):485-496. PubMed ID: 38528257
[TBL] [Abstract][Full Text] [Related]
59. Dupilumab Provides Clinically Meaningful Responses in Children Aged 6-11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial.
Siegfried EC; Cork MJ; Katoh N; Zhang H; Chuang CC; Thomas RB; Rossi AB; Cyr SL; Zhang A
Am J Clin Dermatol; 2023 Sep; 24(5):787-798. PubMed ID: 37300760
[TBL] [Abstract][Full Text] [Related]
60. Dupilumab for atopic dermatitis: evidence to date.
Rodrigues MA; Nogueira M; Torres T
G Ital Dermatol Venereol; 2019 Dec; 154(6):696-713. PubMed ID: 31210470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
